Kindbody: Promise, Rapid Growth, and Clinical Failures

Kindbody was once one of the fastest-growing fertility chains in the US. The venture-backed company cultivated a modern and millennial-friendly aesthetic that helped it attract more than $300 million in investments, including backing from celebrity investors like Gwyneth Paltrow and Chelsea Clinton. But Kindbody has been riddled with clinical problems, with embryos being mislabeled, lost or accidentally destroyed, and has spiraled into crisis. As more people seek fertility treatment than ever, the startup's story illustrates the dangers of moving fast in a largely unregulated industry. 

See omnystudio.com/listener for privacy information.